Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Parrott

Showing results (61-70 of 125) with videos related to

Pageof 13
Sort By:
Journal of Pharmaceutical Sciences|July 26, 2024
Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug on BioavailabilityFlorentin Lukas Holzem, Neil Parrott, Jeannine Petrig Schaffland, et al.
Clinical Pharmacokinetics|February 11, 2025
Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib PharmacokineticsAgustos C Ozbey, Georgina Meneses-Lorente, Brian Simmons, et al.
Journal of Pharmaceutical Sciences|November 29, 2019
Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case StudiesAmitava Mitra, Neil Parrott, Neil Miller, et al.
The AAPS Journal|January 24, 2019
PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry PerspectiveCordula Stillhart, Xavier Pepin, Christophe Tistaert, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 2, 2022
Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating ProfilesAynur Ekiciler, Wen Li Kelly Chen, Yan Bo, et al.
Clinical Pharmacokinetics|August 11, 2011
Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infantsNeil Parrott, Brian Davies, Gerhard Hoffmann, et al.
Current Pharmacology Reports|March 7, 2017
Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current OpportunitiesStephen Fowler, Peter N Morcos, Yumi Cleary, et al.
The AAPS Journal|February 5, 2020
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue DistributionEstelle Yau, Andrés Olivares-Morales, Michael Gertz, et al.
Clinical Pharmacokinetics|September 6, 2015
Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling PredictionsChristophe Boetsch, Neil Parrott, Stephen Fowler, et al.
Clinical Pharmacokinetics|December 31, 2015
Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an ExampleSheng Feng, Jun Shi, Neil Parrott, et al.
Pageof 13

Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
Journal of Pharmaceutical Sciences|July 26, 2024
Oral Absorption from Surfactant-Based Drug Formulations: The Impact of Molecularly Dissolved Drug on BioavailabilityFlorentin Lukas Holzem, Neil Parrott, Jeannine Petrig Schaffland, et al.
Clinical Pharmacokinetics|February 11, 2025
Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib PharmacokineticsAgustos C Ozbey, Georgina Meneses-Lorente, Brian Simmons, et al.
Journal of Pharmaceutical Sciences|November 29, 2019
Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case StudiesAmitava Mitra, Neil Parrott, Neil Miller, et al.
The AAPS Journal|January 24, 2019
PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry PerspectiveCordula Stillhart, Xavier Pepin, Christophe Tistaert, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 2, 2022
Quantitative Cytochrome P450 3A4 Induction Risk Assessment Using Human Hepatocytes Complemented with Pregnane X Receptor-Activating ProfilesAynur Ekiciler, Wen Li Kelly Chen, Yan Bo, et al.
Clinical Pharmacokinetics|August 11, 2011
Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infantsNeil Parrott, Brian Davies, Gerhard Hoffmann, et al.
Current Pharmacology Reports|March 7, 2017
Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current OpportunitiesStephen Fowler, Peter N Morcos, Yumi Cleary, et al.
The AAPS Journal|February 5, 2020
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue DistributionEstelle Yau, Andrés Olivares-Morales, Michael Gertz, et al.
Clinical Pharmacokinetics|September 6, 2015
Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling PredictionsChristophe Boetsch, Neil Parrott, Stephen Fowler, et al.
Clinical Pharmacokinetics|December 31, 2015
Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an ExampleSheng Feng, Jun Shi, Neil Parrott, et al.
Pageof 13